CEBPZ and acute myeloid leukemia: Several prognostic factors are associated with CBF-AML outcomes, such as age, white blood cell (WBC) count at diagnosis, cooperative tyrosine-kinase mutations (KIT, FLT3, N/KRAS) or clonal architecture[15–22].